Analyst firms · Wells Fargo · CL
Wells Fargo CL price target and rating history
Colgate-Palmolive Company (CL) · Consumer Discretionary
Wells Fargo rates Colgate-Palmolive Company (CL) Equal Weight with a $86 price target, as of its latest action on Jan 13, 2026. It has published 4 rating actions on CL since January 2022, including 2 upgrades and 1 downgrade. Across 7 firms with a CL price target in the last 12 months, the median target is $88. Wells Fargo's $86 is 2% below that.
- Current rating
- Equal Weight
- Price target
- $86
- Median target, all firms
- $88
- Actions on CL
- 4
Wells Fargo price target on CL
Every Wells Fargo rating on CL
- Jan 13, 2026
- Sep 16, 2024
- Aug 1, 2022
- Jan 31, 2022
How other firms rate CL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Bernstein | Mkt Perform | $96 | Jun 12, 2026 |
| Rothschild & Co Redburn | Buy | $100 | Apr 21, 2026 |
| TD Cowen | Hold | $85 | Mar 31, 2026 |
| Deutsche Bank | Buy | $98 | Mar 30, 2026 |
| Wells Fargo | Equal Weight | $86 | Jan 13, 2026 |
| Piper Sandler | Overweight | $88 | Jan 7, 2026 |
| Argus Research | Hold | Dec 11, 2025 | |
| RBC Capital Markets | Outperform | $88 | Dec 9, 2025 |
Questions about Wells Fargo and CL
- What is Wells Fargo's price target for CL?
- Wells Fargo's latest stated price target for Colgate-Palmolive Company (CL) is $86, from its action on Jan 13, 2026.
- What is Wells Fargo's rating on CL?
- Wells Fargo rates CL Equal Weight, a neutral rating, as of Jan 13, 2026.
- When did Wells Fargo last change its view on CL?
- On Jan 13, 2026, Wells Fargo upgrades to Equal Weight from Underweight, price target $86.
- How does Wells Fargo's CL target compare with other analysts?
- Across 7 firms with a CL price target in the last 12 months, the median target is $88. Wells Fargo's $86 is 2% below that.
More CL rating histories
All Wells Fargo ratingsCL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.